Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.5Last Year’s EPS
-1.75Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: 21.67%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements in clinical trials and a strong financial position. However, there are challenges related to operational cash use and the inherent risks in clinical and regulatory processes.Company Guidance
During the Amylyx Pharmaceuticals' Fourth Quarter and Full Year 2024 Earnings Conference Call, the company provided guidance on several key metrics and upcoming milestones. The company raised approximately $65.5 million to support commercial preparations for avexitide, aiming to extend its cash runway through 2026. They are conducting four ongoing clinical trials, focusing on orphan diseases. The pivotal Phase III LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH) began recruiting in February 2025, with top-line data expected in the first half of 2026. Avexitide has a 53% reduction in Level 2 and a 66% reduction in Level 3 hypoglycemic events. AMX0035 is being evaluated for Wolfram syndrome and progressive supranuclear palsy (PSP) with Phase II and III trials expected to show significant results. The financial outlook shows operating expenses for Q4 2024 were $39.9 million, a 62% decrease from the previous year, with a solid cash position of $176.5 million at the end of 2024, excluding new financing. The company anticipates commercial launch in 2027, assuming positive outcomes from ongoing trials.Strong Financial Position
Amylyx ended 2024 with a solid cash position of $176.5 million, not including $65.5 million from a recent public offering, securing a runway through 2026.
Avexitide Advancements
Phase III LUCIDITY trial for avexitide in PBH is underway, with significant reductions in hypoglycemic events in previous trials (53% reduction in Level 2 and 66% in Level 3 events).
Pipeline Progress
Key milestones expected within 12-15 months across multiple programs: avexitide, AMX0035, and AMX0114.
Successful Financing
Raised approximately $65.5 million to support commercial preparations for avexitide and extend cash runway.
---
AMLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $3.00 | $3.01 | +0.33% |
| Nov 07, 2024 | $6.22 | $6.54 | +5.14% |
| Aug 08, 2024 | $1.88 | $1.80 | -4.26% |
| May 09, 2024 | $1.93 | $1.89 | -2.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amylyx Pharmaceuticals Inc (AMLX) report earnings?
Amylyx Pharmaceuticals Inc (AMLX) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Amylyx Pharmaceuticals Inc (AMLX) earnings time?
Amylyx Pharmaceuticals Inc (AMLX) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMLX EPS forecast?
AMLX EPS forecast for the fiscal quarter 2025 (Q1) is -0.5.
---
